Venkat Pasnoori, MD
Interventional Cardiology · Kansas City, KSNPI 1740236710
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,748 of the $20,763 with a category attached, or 85.5%. It is spread thinly across 49 manufacturers, the largest accounting for just 14.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $5,321 and has fallen 59.9% since, to $2,134 in 2025.
Across 823 payments — averaging $25.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Biotronik Inc.$2K
- Johnson & Johnson$2K
- Medtronic$1K
- Amgen$1K
- Novartis$1K
- plus $10K from 43 others
What the payments were for
- Travel & lodging$2,92414%
- Food & beverage$17,74885%
- Education$910%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNILINK ELITE$2,022
- Micra$839
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$614
- Peripheral Orbital Atherectomy System$452
- Solia$266
- Rivacor$154
- Acticor$154
- Edora$154
- BioMonitor$154
- Impella$146
- XARELTO$133
- FFRct$124
- Repatha$116
- Selectra$113
- SUPERA$110
How this compares
$20,763 in reported general payments places this provider in the 70th percentile of 55 interventional cardiology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 533 | $475,706 |
| JardianceEmpagliflozin | 241 | $190,365 |
| EntrestoSacubitril/Valsartan | 200 | $176,074 |
| XareltoRivaroxaban | 111 | $98,645 |
| Repatha SureclickEvolocumab | 48 | $34,840 |
| MultaqDronedarone Hcl | 25 | $33,258 |
| Repatha SyringeEvolocumab | 14 | $13,076 |
| BrilintaTicagrelor | 11 | $11,485 |
| VerquvoVericiguat | 11 | $7,206 |
| LivaloPitavastatin Calcium | 13 | $4,058 |
| Amiodarone Hcl | 265 | $3,718 |
| Ranolazine ErRanolazine | 32 | $2,936 |
| Metoprolol Succinate | 393 | $2,726 |
| Atorvastatin Calcium | 336 | $2,505 |
| Flecainide Acetate | 61 | $2,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $760 | $475,706533 claims |
| Boehringer IngelheimJardiance | $797 | $190,365241 claims |
| NovartisEntresto | $1,251 | $176,074200 claims |
| Johnson & JohnsonXarelto | $1,667 | $98,645111 claims |
| Sanofi-aventis U.S. LLCMultaq | $908 | $33,25825 claims |
| AstraZenecaBrilinta | $598 | $11,48511 claims |
| MerckVerquvo | $765 | $7,20611 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $105 | $4,05813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 55 interventional cardiology providers in Kansas.
Other interventional cardiology in Kansas City
- Anthony SpaedyKansas City$385K
- Prasad GunasekaranKansas City$76K
- Kamal GuptaKansas City$46K
- Mark WileyKansas City$39K
- John SerfasKansas City$31K
- Peter TadrosKansas City$20K
- Eric HockstadKansas City$15K
- Georges HajjKansas City$5K
- Ashwani MehtaKansas City$4K
- Maheedhar GedelaWichita$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.